vs
Side-by-side financial comparison of ALBANY INTERNATIONAL CORP (AIN) and ANI PHARMACEUTICALS INC (ANIP). Click either name above to swap in a different company.
ALBANY INTERNATIONAL CORP is the larger business by last-quarter revenue ($321.2M vs $247.1M, roughly 1.3× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 4.3%, a 6.8% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 12.0%). ALBANY INTERNATIONAL CORP produced more free cash flow last quarter ($51.4M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 1.2%).
Albany International Corp is a global advanced materials and industrial technology company. It operates two core segments: Machine Clothing producing custom engineered fabrics for paper and other industrial manufacturing processes, and Engineered Composites developing high-performance composite components primarily for the aerospace and defense sectors, serving customers across North America, Europe, Asia and other global regions.
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
AIN vs ANIP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $321.2M | $247.1M |
| Net Profit | $13.9M | $27.5M |
| Gross Margin | 31.1% | — |
| Operating Margin | 9.3% | 14.1% |
| Net Margin | 4.3% | 11.1% |
| Revenue YoY | 12.0% | 29.6% |
| Net Profit YoY | -21.5% | 367.5% |
| EPS (diluted) | $0.56 | $1.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $321.2M | $247.1M | ||
| Q3 25 | $261.4M | $227.8M | ||
| Q2 25 | $311.4M | $211.4M | ||
| Q1 25 | $288.8M | $197.1M | ||
| Q4 24 | $286.9M | $190.6M | ||
| Q3 24 | $298.4M | $148.3M | ||
| Q2 24 | $332.0M | $138.0M | ||
| Q1 24 | $313.3M | $137.4M |
| Q4 25 | $13.9M | $27.5M | ||
| Q3 25 | $-97.8M | $26.6M | ||
| Q2 25 | $9.2M | $8.5M | ||
| Q1 25 | $17.4M | $15.7M | ||
| Q4 24 | $17.7M | $-10.3M | ||
| Q3 24 | $18.0M | $-24.2M | ||
| Q2 24 | $24.6M | $-2.3M | ||
| Q1 24 | $27.3M | $18.2M |
| Q4 25 | 31.1% | — | ||
| Q3 25 | -19.1% | — | ||
| Q2 25 | 31.3% | — | ||
| Q1 25 | 33.4% | — | ||
| Q4 24 | 31.5% | — | ||
| Q3 24 | 30.3% | — | ||
| Q2 24 | 33.9% | — | ||
| Q1 24 | 34.7% | — |
| Q4 25 | 9.3% | 14.1% | ||
| Q3 25 | -44.6% | 15.9% | ||
| Q2 25 | 7.2% | 6.6% | ||
| Q1 25 | 9.8% | 13.3% | ||
| Q4 24 | 8.5% | -2.3% | ||
| Q3 24 | 8.4% | -13.8% | ||
| Q2 24 | 12.9% | 3.7% | ||
| Q1 24 | 12.4% | 14.8% |
| Q4 25 | 4.3% | 11.1% | ||
| Q3 25 | -37.4% | 11.7% | ||
| Q2 25 | 2.9% | 4.0% | ||
| Q1 25 | 6.0% | 8.0% | ||
| Q4 24 | 6.2% | -5.4% | ||
| Q3 24 | 6.0% | -16.3% | ||
| Q2 24 | 7.4% | -1.7% | ||
| Q1 24 | 8.7% | 13.2% |
| Q4 25 | $0.56 | $1.14 | ||
| Q3 25 | $-3.37 | $1.13 | ||
| Q2 25 | $0.31 | $0.36 | ||
| Q1 25 | $0.56 | $0.69 | ||
| Q4 24 | $0.57 | $-0.45 | ||
| Q3 24 | $0.57 | $-1.27 | ||
| Q2 24 | $0.79 | $-0.14 | ||
| Q1 24 | $0.87 | $0.82 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $112.3M | $285.6M |
| Total DebtLower is stronger | $455.7M | — |
| Stockholders' EquityBook value | $726.2M | $540.7M |
| Total Assets | $1.7B | $1.4B |
| Debt / EquityLower = less leverage | 0.63× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $112.3M | $285.6M | ||
| Q3 25 | $108.3M | $262.6M | ||
| Q2 25 | $106.7M | $217.8M | ||
| Q1 25 | $119.4M | $149.8M | ||
| Q4 24 | $115.3M | $144.9M | ||
| Q3 24 | $127.2M | $145.0M | ||
| Q2 24 | $116.4M | $240.1M | ||
| Q1 24 | $125.4M | $228.6M |
| Q4 25 | $455.7M | — | ||
| Q3 25 | $480.6M | — | ||
| Q2 25 | $444.7M | — | ||
| Q1 25 | $416.4M | — | ||
| Q4 24 | $318.5M | — | ||
| Q3 24 | $362.2M | — | ||
| Q2 24 | $377.1M | — | ||
| Q1 24 | $439.1M | — |
| Q4 25 | $726.2M | $540.7M | ||
| Q3 25 | $739.3M | $505.8M | ||
| Q2 25 | $888.6M | $436.8M | ||
| Q1 25 | $900.0M | $418.6M | ||
| Q4 24 | $943.5M | $403.7M | ||
| Q3 24 | $991.0M | $405.9M | ||
| Q2 24 | $967.5M | $455.8M | ||
| Q1 24 | $967.5M | $452.0M |
| Q4 25 | $1.7B | $1.4B | ||
| Q3 25 | $1.7B | $1.4B | ||
| Q2 25 | $1.7B | $1.3B | ||
| Q1 25 | $1.7B | $1.3B | ||
| Q4 24 | $1.6B | $1.3B | ||
| Q3 24 | $1.8B | $1.3B | ||
| Q2 24 | $1.8B | $920.8M | ||
| Q1 24 | $1.8B | $914.5M |
| Q4 25 | 0.63× | — | ||
| Q3 25 | 0.65× | — | ||
| Q2 25 | 0.50× | — | ||
| Q1 25 | 0.46× | — | ||
| Q4 24 | 0.34× | — | ||
| Q3 24 | 0.37× | — | ||
| Q2 24 | 0.39× | — | ||
| Q1 24 | 0.45× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $73.7M | $30.4M |
| Free Cash FlowOCF − Capex | $51.4M | $29.1M |
| FCF MarginFCF / Revenue | 16.0% | 11.8% |
| Capex IntensityCapex / Revenue | 6.9% | 0.5% |
| Cash ConversionOCF / Net Profit | 5.31× | 1.10× |
| TTM Free Cash FlowTrailing 4 quarters | $82.6M | $171.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $73.7M | $30.4M | ||
| Q3 25 | $43.9M | $44.1M | ||
| Q2 25 | $32.7M | $75.8M | ||
| Q1 25 | $2.1M | $35.0M | ||
| Q4 24 | $78.5M | $15.9M | ||
| Q3 24 | $47.0M | $12.5M | ||
| Q2 24 | $83.4M | $17.4M | ||
| Q1 24 | $9.6M | $18.3M |
| Q4 25 | $51.4M | $29.1M | ||
| Q3 25 | $25.9M | $38.0M | ||
| Q2 25 | $18.8M | $71.8M | ||
| Q1 25 | $-13.5M | $32.5M | ||
| Q4 24 | $60.2M | $13.5M | ||
| Q3 24 | $31.6M | $7.7M | ||
| Q2 24 | $63.6M | $13.0M | ||
| Q1 24 | $-17.3M | $13.7M |
| Q4 25 | 16.0% | 11.8% | ||
| Q3 25 | 9.9% | 16.7% | ||
| Q2 25 | 6.0% | 34.0% | ||
| Q1 25 | -4.7% | 16.5% | ||
| Q4 24 | 21.0% | 7.1% | ||
| Q3 24 | 10.6% | 5.2% | ||
| Q2 24 | 19.2% | 9.4% | ||
| Q1 24 | -5.5% | 10.0% |
| Q4 25 | 6.9% | 0.5% | ||
| Q3 25 | 6.9% | 2.7% | ||
| Q2 25 | 4.5% | 1.9% | ||
| Q1 25 | 5.4% | 1.3% | ||
| Q4 24 | 6.4% | 1.3% | ||
| Q3 24 | 5.2% | 3.2% | ||
| Q2 24 | 6.0% | 3.2% | ||
| Q1 24 | 8.6% | 3.3% |
| Q4 25 | 5.31× | 1.10× | ||
| Q3 25 | — | 1.66× | ||
| Q2 25 | 3.56× | 8.87× | ||
| Q1 25 | 0.12× | 2.23× | ||
| Q4 24 | 4.44× | — | ||
| Q3 24 | 2.61× | — | ||
| Q2 24 | 3.39× | — | ||
| Q1 24 | 0.35× | 1.00× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AIN
| Transferred At Point In Time | $176.5M | 55% |
| Engineered Composites Other | $99.3M | 31% |
| Engineered Composites ASC | $44.5M | 14% |
| Transferred Over Time | $1.0M | 0% |
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
